Friday afternoon Programme
|
|
- Arleen Greene
- 5 years ago
- Views:
Transcription
1 Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008 Jurys Hotel, Bristol 1
2 Phones on silent please Pharmacology & TDM Dr Marta Boffito Chelsea & Westminster Hospital 2
3 Miss X Ex- IVDU HIV+ since 1996 Several treatments in the past, including dual NRTI therapy Intolerant to low dose RTV Refuses T-20 CD4 160 VL 70,000 Currently off therapy What tests? 1. Repeat CD4 count and viral load 2. Urine drug screen and HIV tropism 3. Resistance test 4. Resistant test and HIV tropism 5. None 3
4 Resistance Test NRTI / NtRTI mutations 41L, 67G, 70R, 210W, 215Y 74V 184V 44D +118I 69A NNRTI mutations 103N, 106I PI mutations Major: I50V, L90M Minor: L10V, L33F Other: I13V, K20R, M36I, L89I N-Nt RTI 3TC Resistance ABC Resistance AZT Resistance D4T Resistance DDI Resistance FTC Resistance TDF Intermediate resistance NNRTI EFV High-level resistance ETV Potential low-level resistance NVP High-level resistance 4
5 Protease Inhibitors ATV Low-level resistance DRV Intermediate resistance FPV High-level resistance IDV Low-level resistance LPV Intermediate resistance NFV Intermediate resistance SQV Intermediate resistance TPV Potential low-level resistance What drug classes? 1. NRTI + boosted PI 2. NRTI + NNRTI 3. NNRTI + PI/r + integrase inhibitor 4. NNRTI + PI* + integrase inhibitor + CCR5-ant 5. PI* + integrase inhibitor + CCR5-ant *unboosted 5
6 Active/available agents Tenofovir? TDF/FTC? Etravirine 200 mg BID Raltegravir 400 mg BID Atazanavir 400 or 300/100 mg OD? Maraviroc what dose? What drugs (previous slide) cannot be co-administered? 1. FTC and raltegravir 2. Etravirine and atazanavir 3. Etravirine and maraviroc 4. Etravirine and raltegravir 5. Tenofovir and atazanavir/ritonavir 6
7 Effect of PIs on ETV 80% TMC125 Cmin increased by 58 and 25% 60% 50% 51% Change in ETV AUC 40% 20% 0% -20% -40% -60% -80% TPV/r -76% Full-dose RTV -46% DRV/r -37% 17% 30% LPV/r ATV/r ATV IDV Comparable to historic control FPV/r No dose adjustment necessary Dose adjustment or alternative may be necessary Contraindicated Kakuda et al Effect of ETV on PIs 80% 60% ATV Cmin decreased by 47 and 38% 69% Change in PI AUC 40% 20% 0% -20% -40% -60% -80% SQV SQV IDV LPV/r LPV/r ATV ATV/r -52% -46% -13% -18% -20% -17% -14% 6% 18% DRV/r TPV/r FPV/r No dose adjustment necessary Dose adjustment or alternative may be necessary Contraindicated Kakuda et al
8 ATV + TDF When ATV 400 mg + TFV co-administered ATV C min decreases by 28-40% When co-dosed with TDF, ATV should be combined with RTV The decrease in ATV C min is 25% ATV dose increase in experienced pts has been taken into consideration t1 PK evaluation of ETV and raltegravir in healthy volunteers 1,000 10,000 ETV (ng/ml) ETV + RAL ETV alone Time (hours) RAL (ng/ml) 1, ETV + RAL RAL alone Time (hours) Anderson et al
9 Slide 16 t1 Although the researchers figured that a 34% lower raltegravir trough with etravirine than without it should not necessitate a dose adjustment, the 90% confidence interval around that trough (0.34 to 1.26) indicates wide trough variability from person to person, not an unusual finding in these kinds of studies. Still, the reported variability means raltegravir troughs fell up to two thirds lower with etravirine than without it in a few people, and for those few people one would have less confidence saying the change lacks clinical meaning. temp, 03/12/2007
10 Raltegravir + ATV RAL % change C 12 AUC C max ATV/r ATV unboosted Isentress Prescribing Information Miss X TVD 1 tablet OD ETV 200 mg BID RAL 400 mg BID ATV/r 300/100 mg OD PLAN: when VL< 50 and tropism available, REPLACE ATV/r WITH MRV 9
11 Other drugs 2 days before re-starting you receive a letter from her GP saying that the methadone dose has been reduced to 50 mg daily What do you do now? 1. Prescribe only NRTIs 2. Avoid NNRTIs 3. Consult HIV-druginteractions.org 4. Write to GP to increase methadone dose 5. Refer the patient to Dr Pozniak 10
12 Etravirine and methadone No dose adjustments required Clinical monitoring for withdrawal symptoms is recommended Co-administration - increased: C max, AUC, C min of R-methadone by 2-10% - decreased: C max, AUC, C min of S-methadone by 11% 11
13 Maraviroc drug interaction summary Interacting Drug Saquinavir/r Atazanavir/r Lopinavir/r Tipranavir/r Ritonavir LPV/r + efavirenz Efavirenz Nevirapine Tenofovir Rifampicin Effect of other ARV on MRV AUC 10-fold 4.9-fold 4.0-fold 2.0-fold 2.5-fold 50% 70% Abel et al t2 Maraviroc + etravirine Effect of ETV on MRV PKs C max AUC Data consistent with ETV acting as a potent inducer of MRV metabolism In the absence of potent CYP3A4 inhibitors such as RTV, the recommended clinical dose for MRV is 600 mg BID Davis et al
14 Slide 24 t2 Co-administration of etravirine with maraviroc decreased the exposure of maraviroc by 53% and 60% for AUC12 and Cmax respectively compared to maraviroc alone. These data are consistent with etravirine acting as a potent inducer of the metabolism of maraviroc. As such, in the absence of potent CYP3A4 inhibitors such as protease inhibitors, the recommended clinical dose for maraviroc is 600 mg bid. temp, 26/11/2007
15 t3 Maraviroc + etravirine + darunavir/ritonavir Effect of ETV + DRV/r on MRV PKs C max AUC Net increase in MRV concentrations consistent with previous inducer/inhibitor combination data: effect appears to be inhibition Recommended clinical dose for MRV in the presence of boosted PIs is 150 mg BID What dose of maraviroc? mg BID mg BID mg OD mg BID mg BID 13
16 Slide 25 t3 Co-administration of etravirine/darunavir/ritonavir with maraviroc increased the exposure of maraviroc by 210% and 77% for AUC12 and Cmax respectively compared to maraviroc alone. These results, where the combination of a potent inducer of CYP mediated metabolism (etravirine) and a potent inhibitor of CYP mediated metabolism (darunavir / ritonavir) yields a net increase in maraviroc concentrations, are consistent with previous inducer/inhibitor combination data, where the net effect appears to be inhibition. As such, the recommended clinical dose for maraviroc in the presence of boosted PIs (including etravirine/darunavir/ritonavir) should be 150mg bid. TMC125 pharmacokinetic data showed no effect of maraviroc on TMC125 pharmacokinetics. Therefore, no dose adjustment of TMC125 is necessary. The dose remains 200 mg b.i.d.. temp, 26/11/2007
17 Summary of dose modifications with maraviroc Concomitant treatment Includes a potent CYP3A4 inhibitor For example: Protease inhibitors* ± ritonavir (except tipranavir) Elvitegravir, delavirdine Ketoconazole, itraconazole, clarithromycin, telithromycin, nefazadone, telithromycin YES Regardless of other agents in the regimen Morning dose 150 mg Evening dose 150 mg NO Includes a CYP3A4 inducer For example: Efavirenz, etravirine Rifampicin NO NO CYP3A4 inhibitors or inducers For example: NRTIs, also nevirapine, tipranavir/r YES 300 mg 300 mg 300 mg 300 mg 300 mg 300 mg *including darunavir Davis et al
18 E. C. Male, HIV+ since 2004 CD4 211 (17%) cells/mm 3 VL 29,000 copies/ml History of epilepsy Stable on carbamazepine (Ca) and phenytoin (Ph) 15
19 E. C. Ca and Ph are inducers of different CYP450 enzymes (CYP3A4) Metabolized by CYP3A4 Interaction between Ca and EFV documented EFV and carbamazepine Arm Drug PK parameter GMR and 90% CI EFV + CBZ vs. EFV CBZ + EFV vs. CBZ A* EFV C max AUC C min ( ) ( ) ( ) B** CBZ C max AUC C min ( ) ( ) ( ) CBZE^ C max AUC C min ( ) ( ) ( ) ^CBZE = carbamazepine epoxide *n=18, EFV 600 mg OD days 1-14, EFV 600 mg OD days plus carb 200 first then 400 mg OD up to day 35 **n=18, carb 200 first then 400 mg OD up to day 21, carb 400 mg OD plus EFV 600 mg days Kaul et al
20 E. C. Ca and Ph are inducers of different CYP450 enzymes (CYP3A4) Metabolized by CYP3A4 Interaction between Ca and EFV documented Interaction between Ph and LPV/r documented Phenytoin and LPV/r LPV/r alone LPV/r + phenytoin Phenytoin alone Phenytoin + LPV/r [Lopinavir] µg/m [Phenytoin] µg/m Time (h) Time (h) Phenytoin was also found to reduce the concentration of RTV Lim et al
21 What are the options for E. C.? 1) Stop Ca and Ph and prescribe alternative antiepileptic (i.e. levetiracetam) 2) Valproate and lamotrigine might be safe with NNRTI (more data needed) 3) Initiate a 4 NRTI regimen for HIV (i.e. AZT/3TC/ABC/TDF) 4) Other? R. E. Male, HIV+ 1 month ago CD4 101 (15%) cells/mm 3 VL 89,000 copies/ml Primary transmitted resistance (103N) Recreational drugs: ectasy (MDMA) 18
22 R. E. MDMA metabolized CYP2D6, CYP1A2, CYP2B6, CYP3A4 RTV inhibits CYP3A4 & CYP2D6 Caution when prescribing PI/r Systemic circulation heart rate BP Tremor Sweating Bruxism Hyperthermia Rhabdomyolysis Intravasc. coagulation Acute Renal failure Ecstasy CYP2D6 CYP3A4 RTV Portal vein 19
23 G. B. 55 year old HIV+ (since 1998) male On TDF/FTC/LPV/r CD4 210 cells/mm 3 ; VL < 50 copies/ml History of depression currently untreated Admitted to A&E complaining of vomiting, extreme weakness, palpitations, confusion Few days later comes to HIV clinic for regular follow up and reports recent anxiety attacks My GP gave me this G. B. Propranolol 40 mg RTV CYP2D6 COMMUNICATION BETWEEN HIV SPECIALISTS AND GP 20
24 Patient Case HIV+ (1994) 32 y.o. Cx M 2/ /2003 d4t + 3TC + NVP VL 50,000 RT: 75I, 98S, 181C, 184V, 221Y 10/2003 5/2005 TDF + ddi + LPV/r TDF + FTC + ATV/r (1) Patient happy with his OD regimen Complains of heartburn Ranitidine 150 mg BD prescribed (2) (2) (1) (3) In ATV/r Would H.V, + ATV FAM you AUC 40 switch mg and BDC min in the H.V: by PI ATV 25% to AUC, and one 26% that C max compared, does C min not 18%, to ATV/r interact 14%, 300/100 28% with mg HIV Efficacy H 2 blocker patients-intragastric of ATV/r and + TDF? in ph treatmentexperienced patients demonstrated in higher? in ATV may study be avoided by temporal separation of ATV/r and FAM-BD? TDM: ATV C trough : 98 (MEC = 150 ng/ml) (3) CD4 528 VL<50 5/2005 7/2006 8/2006 Time (month) 1.Johnson M, et al. AIDS 2005;19: Patient Case HIV+ (1994) 38 y.o. Cx M CD4 189, VL 130,000 Wild type (1) (2) (3) In ATV/r Inter H.V, + individual ATV FAM AUC 40 mg and BD variability C min in H.V: by ATV 25% in and AUC, 26% C max compared, C min 18%, to ATV/r 14%, 300/100 28% mg drug levels and interaction Efficacy HIV outcomes patients-intragastric of ATV/r + TDF in ph treatmentexperienced patients demonstrated in higher? in ATV may be avoided by temporal study 045 separation of ATV/r and FAM-BD? TDF + FTC + ATV/r (1) Patient happy with his OD regimen, Sees his GP because of heartburn GP prescribes ranitidine 150 mg BD (2) ATV C trough : 405 (MEC = 150 ng/ml) (3) CD4 333 VL<50 12/2004 9/2006 Time (month) 10/ Johnson M, et al. AIDS 2005;19:
A clinical guide to managing drugdrug interactions in antiretroviral therapy
HIVPA 2008, 6 th June 2008 HIV Pharmacology and TDM B Marta Boffito MD PhD St. Stephen s Centre Chelsea and Westminster Hospital, London A clinical guide to managing drugdrug interactions in antiretroviral
More informationClinical Management of Drug-Drug Interactions. Marta Boffito (UK)
Clinical Management of Drug-Drug Interactions Marta Boffito (UK) Mr Case A 34 year old man from NZ HIV+ since 2006 Hx of depression, currently untreated CD4 201 (14%), VL 206,000 Clade B Baseline RT Therefore
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationClinical Pharmacology of Integrase Inhibitors
Clinical Pharmacology of Integrase Inhibitors Dr Marta Boffito MD PhD Head of Clinical Trials, St Stephen Centre (SSAT) Consultant Physician, Chelsea and Westminster Foundation Trust Reader, Imperial College
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationDrug-Drug Interactions that Matter
Perspective Drug-Drug Interactions that Matter It is increasingly difficult to keep track of information on drug-drug interactions in HIV therapeutics, and the clinical implications of much of the data
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHIV for the Non-ID Pharmacist
Disclosures HIV for the Non-ID Pharmacist I have nothing to disclose at this time Carmen Faulkner-Fennell, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist--Infectious Diseases Greenville Hospital System
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationThe New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationUpdate on Antiretroviral Treatment for HIV Infection 2008
Update on Antiretroviral Treatment for HIV Infection 2008 Janet Gilmour MD FRCP(C) Clinical Associate Professor of Medicine University of Calgary November 2008 Disclosure and Acknowledgements Disclosure:
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationKiat Ruxrungtham. Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre
Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre www.iasusa.org; www.aidsinfo.nih.gov; www.clinicaloptions.com; www.clinicaloptions.com/hiv
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationSasisopin Kiertiburanakul, MD, MHS
What s Newin Antiretroviral Therapy? Sasisopin Kiertiburanakul, MD, MHS Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Rotating RCPT,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More informationWhen to start, when to switch ART and monitoring of ARV side effects
When to start, when to switch ART and monitoring of ARV side effects Thanomsak Anekthananon, MD Faculty of Medicine Siriraj Hospital September 4, 2009 Recommended Websites Free e-book: HIV Medicine 2007
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationDRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR
DRUG INTERACTIONS WITH GRAZOPREVIR AND ELBASVIR Pharmacology NS3/4A protease inhibitor NS5A inhibitor Adult Dose Investigational: 100 mg once daily Investigational: 50 mg once daily Being developed as
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More information/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program
/AIDS HIV/ HIV Overview Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program www.hivresearch.org 1 WRAIR Tropical Medicine Course
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationJosep Mallolas Hospital Clínic Barcelona
Nuevos paradigmas en la infección VIH Josep Mallolas Hospital Clínic Barcelona 1. Do you believe, I have to start ARV therapy? Incidence and Mortality of AIDS in Spain HIV and NON-AIDS complications HIV
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationImproving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More informationPersistent low level viraemia on third line ART
Persistent low level viraemia on third line ART Dr Richard Lessells XXVII International workshop on HIV drug resistance and treatment strategies October 2018 46-year old HIV-positive female HIV diagnosis
More informationAntiretroviral Therapy
Antiretroviral Therapy Shelley A. Gilroy, MD FACP, FIDSA Albany Medical College October 29, 2013 Disclosures Co Investigator for studies at Albany Medical Center sponsored by Gilead and GSK Pharmaceuticals
More informationNew issues in management of drug-drug interactions
New issues in management of drug-drug interactions Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology www.hiv-druginteractions.org Presentation outline mechanisms of drug-drug interactions
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationTHERAPEUTIC DRUG MONITORING (TDM) Table 2. Dose Adjustment. Patient Drug (mg) Symptoms C trough -fold increase compared to MEC WT
1 The Sixth International Congress on Drug Therapy in HIV Infection took place in Glasgow, UK, on November 17-21, 2002. Pharmacological aspects of antiretroviral therapy were covered in both oral and poster
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationA case, and some pharmacological considerations. from the perspective of a virologist. Anna Maria Geretti University of Liverpool, United Kingdom
A case, and some pharmacological considerations. from the perspective of a virologist Anna Maria Geretti University of Liverpool, United Kingdom 1 Case History: Mr RS 53-year-old male Diagnosed HIV positive
More informationSlide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015
Slide 1 Will DAA drug interactions matter in the future? David Back University of Liverpool UK David Back University of Liverpool June 2015 Disclosures Honoraria received for Advisory Boards, lectures
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationHIV infection and Primary Care. HIV Care in /30/2013. It s not the AIDS of 85. Stephen Raffanti MD MPH Vanderbilt University School of Medicine
HIV infection and Primary Care Stephen Raffanti MD MPH Vanderbilt University School of Medicine HIV Care in 2013 Chronic lifelong treatment with all the associated issues: medication tolerability medication
More informationHIV Diagnosis and Management 2015 Update. Faria Farhat, MD MedStar Washington Hospital Center
HIV Diagnosis and Management 2015 Update Faria Farhat, MD MedStar Washington Hospital Center Objectives Describe the epidemiology and pathogenesis of HIV infection Highlight HIV diagnosis algorithm and
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationClinical Notes, management of HIV/HCV patients in real life
HCV TREATMENT: OPEN QUESTIONS Clinical Notes, management of HIV/HCV patients in real life Letizia Marinaro Malattie infettive Ospedale Amedeo Di Savoia, Turin 11 TH RESIDENTIAL COURSE ON CLINICAL PHARMACOLOGY
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationAddressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationWESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
More informationManagement of Convulsions in HIV Positive Patients
Management of Convulsions in HIV Positive Patients Dr. Rajendra Prasad Shivaswamy 1, Dr. K A Sudarshan Murthy 2, K H Sahithi 3 1 Assistant Professor, Department of Medicine, JSS Medical College, JSS University,
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationHIV Drug Resistance and How to Manage HAART failure
HIV Drug Resistance and How to Manage HAART failure Kiat Ruxrungtham Professor of Medicine Chulalongkorn University, and HIV-NAT, Thai Red Cross AIDS Research Centre Targets of Antiretroviral Agents RT
More informationA Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
More informationVirological failure in children. Dr Lee Fairlie
Virological failure in children Dr Lee Fairlie Case 1 Thembi is a 34 year old female. She is HIV infected She lives in JHB and her 2 children, Lerato and Sipho live in Mpumalanga with Gogo They are both
More informationPaediatric ART Working Group. guideline review meetings
Paediatric ART Working Group Report back from Sept 2009 and Dec 2009 ART guideline review meetings Paediatric ARV working group priorities Continue to emphasise need for scored adult FDCs this avoids need
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More information